Last reviewed · How we verify
Licensed seasonal influenza vaccine
Licensed seasonal influenza vaccine is a Recombinant protein vaccine with adjuvant Biologic drug developed by Novavax. It is currently FDA-approved for Prevention of seasonal influenza in adults aged 18 years and older.
Novavax's seasonal influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.
Novavax's seasonal influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains. Used for Prevention of seasonal influenza in adults aged 18 years and older.
At a glance
| Generic name | Licensed seasonal influenza vaccine |
|---|---|
| Sponsor | Novavax |
| Drug class | Recombinant protein vaccine with adjuvant |
| Target | Influenza hemagglutinin (HA) protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains recombinant influenza hemagglutinin (HA) protein antigens produced using baculovirus expression technology, combined with Matrix-M adjuvant to enhance immune response. This protein-based approach triggers both humoral and cell-mediated immunity, enabling the body to recognize and neutralize influenza viruses before infection occurs.
Approved indications
- Prevention of seasonal influenza in adults aged 18 years and older
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- H1ssF Flu Vaccine Clinical Trial (PHASE1)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- Revealing Protective Immunity to Influenza Using Systems Immunology (PHASE4)
- A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults (PHASE1)
- Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults (PHASE1)
- Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Licensed seasonal influenza vaccine CI brief — competitive landscape report
- Licensed seasonal influenza vaccine updates RSS · CI watch RSS
- Novavax portfolio CI
Frequently asked questions about Licensed seasonal influenza vaccine
What is Licensed seasonal influenza vaccine?
How does Licensed seasonal influenza vaccine work?
What is Licensed seasonal influenza vaccine used for?
Who makes Licensed seasonal influenza vaccine?
What drug class is Licensed seasonal influenza vaccine in?
What development phase is Licensed seasonal influenza vaccine in?
What are the side effects of Licensed seasonal influenza vaccine?
What does Licensed seasonal influenza vaccine target?
Related
- Drug class: All Recombinant protein vaccine with adjuvant drugs
- Target: All drugs targeting Influenza hemagglutinin (HA) protein
- Manufacturer: Novavax — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of seasonal influenza in adults aged 18 years and older
- Compare: Licensed seasonal influenza vaccine vs similar drugs
- Pricing: Licensed seasonal influenza vaccine cost, discount & access